The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...

and methodology as well as key results and takeaways regarding the role of β-blockers in the multimodal management of these HF types.

Background: Heart failure with preserved ejection fraction (HFpEF) is among the leading causes of cardiovascular mortality and morbidity. Recent multi-omics data sets underscore severely impaired ...

Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients ...

The American College of Cardiology (ACC) and the American Heart Association (AHA) recommend that cardiologists manage heart failure by its stage: There is no cure for HFpEF, but timely management ...

Global Commercial Launch Preparations Underway for First Potential Approval Towards Building Specialty Cardiovascular Franchise Company Recently Launched Unbranded Disease Awareness Campaign “HCM ...

in patients suffering from heart failure with preserved ejection fraction (HFpEF). The study, published in JAMA Cardiology, ...

Opens in a new tab or window The novel investigational weight loss agent HU6 had mixed results specifically targeting obesity-related heart failure with preserved ejection fraction (HFpEF), based ...

As a result, up to 20% of patients with HFpEF might have normal natriuretic peptide levels (eg, N-terminal pro B-type natriuretic peptide [NT-proBNP] <125 ng/L), complicating the diagnosis and ...

A recent study found that tirzepatide, the active ingredient in Zepbound and Mounjaro, could reduce the risk of ...

Introduction: Heart failure with preserved ejection fraction (HFpEF) is a heterogenous clinical syndrome that accounts for nearly half of all heart failure cases world-wide. The pathophysiological ...